Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.

Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD, Beach RK, Lifson JD, Felber BK, Pavlakis GN.

J Biol Chem. 2013 Jun 21;288(25):18093-103. doi: 10.1074/jbc.M113.461756. Epub 2013 May 6.

2.
3.

Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.

Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, Chertova E, Rosenberg SA, Felber BK, Pavlakis GN.

Blood. 2012 Jul 5;120(1):e1-8. doi: 10.1182/blood-2011-10-384362. Epub 2012 Apr 10.

4.

The IL-15 receptor {alpha} chain cytoplasmic domain is critical for normal IL-15Ralpha function but is not required for trans-presentation.

Wu Z, Xue HH, Bernard J, Zeng R, Issakov D, Bollenbacher-Reilley J, Belyakov IM, Oh S, Berzofsky JA, Leonard WJ.

Blood. 2008 Dec 1;112(12):4411-9. doi: 10.1182/blood-2007-03-080697. Epub 2008 Sep 16.

5.

IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.

Tamzalit F, Barbieux I, Plet A, Heim J, Nedellec S, Morisseau S, Jacques Y, Mortier E.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8565-70. doi: 10.1073/pnas.1405514111. Epub 2014 May 27.

6.

Soluble Interleukin IL-15Ralpha is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15.

Bulanova E, Budagian V, Duitman E, Orinska Z, Krause H, Rückert R, Reiling N, Bulfone-Paus S.

J Biol Chem. 2007 May 4;282(18):13167-79. Epub 2007 Feb 27. Retraction in: J Biol Chem. 2011 Feb 18;286(7):5934.

7.

Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.

Sato N, Sabzevari H, Fu S, Ju W, Petrus MN, Bamford RN, Waldmann TA, Tagaya Y.

Blood. 2011 Apr 14;117(15):4032-40. doi: 10.1182/blood-2010-09-307504. Epub 2011 Feb 8.

8.

The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha.

Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, Perdreau H, Jacques Y, Plet A.

J Mol Biol. 2008 Sep 26;382(1):1-12. doi: 10.1016/j.jmb.2008.07.019. Epub 2008 Jul 16.

PMID:
18656487
9.

Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation.

Thaysen-Andersen M, Chertova E, Bergamaschi C, Moh ES, Chertov O, Roser J, Sowder R, Bear J, Lifson J, Packer NH, Felber BK, Pavlakis GN.

Glycoconj J. 2016 Jun;33(3):417-33. doi: 10.1007/s10719-015-9627-1. Epub 2015 Nov 12.

PMID:
26563299
10.

Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Rα in human monocytes and dendritic cells.

Müller JR, Waldmann TA, Kruhlak MJ, Dubois S.

J Biol Chem. 2012 Nov 23;287(48):40328-38. doi: 10.1074/jbc.M112.378612. Epub 2012 Oct 16.

11.

Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.

Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21647-52. doi: 10.1073/pnas.1012128107. Epub 2010 Nov 22.

12.

Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.

Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN.

PLoS One. 2013 Nov 27;8(11):e81768. doi: 10.1371/journal.pone.0081768. eCollection 2013.

13.

Elucidation of the interleukin-15 binding site on its alpha receptor by NMR.

Hanick NA, Rickert M, Varani L, Bankovich AJ, Cochran JR, Kim DM, Surh CD, Garcia KC.

Biochemistry. 2007 Aug 21;46(33):9453-61. Epub 2007 Jul 27.

PMID:
17655329
14.

IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Shi Y, Dincheva-Vogel L, Ayemoba CE, Fung JP, Bergamaschi C, Pavlakis GN, Farzaneh F, Gaensler KML.

Blood Adv. 2018 Nov 27;2(22):3177-3192. doi: 10.1182/bloodadvances.2018019026.

15.

Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.

Votavova P, Tomala J, Kovar M.

Immunol Lett. 2014 May-Jun;159(1-2):1-10. doi: 10.1016/j.imlet.2014.01.017. Epub 2014 Feb 7. Review.

PMID:
24512738
16.

Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.

Stone JD, Chervin AS, Schreiber H, Kranz DM.

Biotechnol Prog. 2012 Nov-Dec;28(6):1588-97. doi: 10.1002/btpr.1631. Epub 2012 Oct 18.

17.

IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.

Mortier E, Woo T, Advincula R, Gozalo S, Ma A.

J Exp Med. 2008 May 12;205(5):1213-25. doi: 10.1084/jem.20071913. Epub 2008 May 5.

18.

IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells.

Chenoweth MJ, Mian MF, Barra NG, Alain T, Sonenberg N, Bramson J, Lichty BD, Richards CD, Ma A, Ashkar AA.

J Immunol. 2012 May 1;188(9):4149-57. doi: 10.4049/jimmunol.1101883. Epub 2012 Mar 23.

19.

Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.

Finch DK, Midha A, Buchanan CL, Cochrane D, Craggs RI, Cruwys S, Grahames C, Kolbeck R, Lowe DC, Maltby J, Pattison DV, Vousden KA, Ward A, Sleeman MA, Mallinder PR.

Br J Pharmacol. 2011 Jan;162(2):480-90. doi: 10.1111/j.1476-5381.2010.01061.x.

20.

IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation.

Wu Z, Xu Y.

J Mol Cell Biol. 2010 Aug;2(4):217-22. doi: 10.1093/jmcb/mjq012.

PMID:
20671116

Supplemental Content

Support Center